医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hotel Nikko Taizhou Opens April 1

2016年03月28日 PM05:30
このエントリーをはてなブックマークに追加


 

TOKYO

Okura Nikko Hotel Management Co., Ltd. announced today the opening of Hotel Nikko Taizhou on April 1. The luxury hotel is located in the center of Taizhou National Medical High-tech Development Zone, China’s first and largest national medical high-tech zone.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160328005306/en/

Hotel Nikko Taizhou (Photo: Business Wire)

Hotel Nikko Taizhou (Photo: Business Wire)

Hotel Nikko Taizhou is Okura Nikko Hotel Management’s 12th property in China following the opening of Hotel Nikko Suzhou in June 2015. It is also the first property in the area operated by an international hotel group.

Hotel Nikko Taizhou will have 200 guest rooms of nine different types. The 18-story, 404,507 square feet (37,580m2) property offers six banquet and meeting rooms, multiple dining facilities, a business center, a fitness club and an indoor pool.

Jo Sato, the General Manager of Hotel Nikko Taizhou, said: “Our warmest Japanese hospitality will ensure that all our guests have an extraordinary, high-quality experience.”

Taizhou National Medical High-tech Development Zone, also known as China Medical City, houses blue-chip global biopharmaceutical companies, research facilities and academic institutions. The precinct is comprised of several major areas as defined by function, including research and development, medical/health services, manufacturing and an exhibition center.

Taizhou, a city of approximately five million people, is located 155 miles (250 km) northwest of Shanghai in central Jiangsu Province, which is about a three-hour drive from Shanghai Hongqiao International Airport.

The hotel was constructed by TAIZHOU TONGTAI INVESTMENT CO., LTD., with which Okura Nikko Hotel Management signed an agreement to manage the hotel in April 2015 through China-based joint-venture company BTG-Nikko International Hotel Management Co., Ltd.

About Okura Nikko Hotel Management

Okura Nikko Hotel Management Co., Ltd., a subsidiary of Hotel Okura Co., Ltd, operates three hotel groups: Okura Hotels & Resorts (26 member hotels), Nikko Hotels International (37 member hotels) and Hotel JAL City (11 member hotels). Founded in October 2015 to consolidate and strengthen its hotel management business, Okura Nikko Hotel Management aims to become the top Japan-based hotel operating company by developing an international portfolio of properties through hotel management contracts. Please visit www.okura-nikko.com for more information.

About Nikko Hotels International

Nikko Hotels International (NHI) is a luxury hotel brand providing facilities and services to meet a wide variety of guests’ needs in urban centers and popular resort destinations worldwide. The NHI brand emphasizes fine luxury, gracious hospitality and international culture. Service in the spirit of Japanese hospitality is a distinguishing feature of all NHI properties, both in Japan and overseas. Please visit www.nikko-jalcity.com/brand/nhi/ for more information.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160328005306/en/

CONTACT

Media Contacts
Okura Nikko Hotel Management Co., Ltd.
Ms.
Shoko Amano / Mr. Ryutaro Suzuki, +81-3-6864-2729
Public Relations
pr@okura-nikko.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果